The stock quoted a 52-week high price of Rs 1063.75 and low of Rs 620.55.
As of 10:10AM (IST), the counter saw total traded volume of 135,440 shares with a traded value of Rs 9.24 crore, according to NSE.
The stock had closed at Rs 669.25 in the previous session.
The scrip has declined -2.21 per cent in the past one month till date, while the benchmark BSE Sensex has slipped -4.88 per cent during the same period.
According to exchange data, the stock traded at a price-to-earnings (P/E) multiple of 7.73 while price-to-book ratio stood at 2.36. A higher P/E ratio shows that investors are willing to pay a higher price for per rupee earnings given by the stock because of better future growth expectations. The price-to-book value indicates the inherent value of a company and it reflects the price investors are ready to pay even for no growth in a business.
The stock belongs to the Pharma – Indian industry.
Promoter/FII Holding
Promoters held 48.76 per cent stake in the company as of 30-Sep-2021, while FII and MF ownership in the firm stood at 21.71 per cent and 9.28 per cent, respectively.
Key Financials
The company reported consolidated sales of Rs 6038.5 crore for the quarter ended 30-Sep-2021, up 4.41 per cent from the previous quarter’s Rs 5783.29 crore and up 7.63 per cent from the year-ago quarter’s Rs 6537.19 crore. Its net profit for the latest quarter stood at Rs 696.99 crore, down 13.55 per cent from the same quarter a year ago.
